Mynewsdesk LinkedIn
Press & News

The next generation biopharmaceuticals

Press releases 2015

Older press releases

2015-12-01

Affibody receives clinical milestone from Daiichi Sankyo

Solna, Sweden, December 1, 2015. Affibody AB announced today that it will receive a clinical milestone in connection with Daiichi Sankyo Company Limited’s (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568) initiation of a Phase I study.[read more]

2015-11-20

Interim Report – January to September 2015

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its its Interim Report for the third quarter...[read more]

2015-08-21

Interim Report – January to June 2015

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its its Interim Report for the second quarter...[read more]

« Older press releases

Affibodys latest Press releases

2021-09-09

Phase 2 LINNAEA Study Presented at EURETINA

Solna, Sweden, September 9, 2021. Affibody AB (“Affibody”) today announced that Professor Quan Dong Nguyen, Principal Coordinating Investigator of...[read more]

Press & News

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

About Affibody

Upcoming reports Financial calendar

  • Interim Report January to March 2020 (May 15, 2020)
  • Interim Report January to June 2020 (August 21, 2020)
  • Interim Report January to September 2020 (November 13, 2020)
  • Year End Report 2020 (February 2021)

Investor information